Meitav Dash Investments Ltd. Sells 3,957 Shares of Mylan NV (NASDAQ:MYL)

Share on StockTwits

Meitav Dash Investments Ltd. trimmed its position in Mylan NV (NASDAQ:MYL) by 3.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,919 shares of the company’s stock after selling 3,957 shares during the quarter. Meitav Dash Investments Ltd.’s holdings in Mylan were worth $1,622,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Watson Rebecca bought a new position in Mylan during the second quarter valued at $26,000. Ameritas Investment Company LLC purchased a new stake in Mylan in the 1st quarter worth about $30,000. CWM LLC lifted its stake in Mylan by 766.9% in the first quarter. CWM LLC now owns 2,748 shares of the company’s stock worth $41,000 after purchasing an additional 2,431 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Mylan by 85.4% during the first quarter. Parallel Advisors LLC now owns 3,005 shares of the company’s stock valued at $44,000 after buying an additional 1,384 shares during the period. Finally, Signaturefd LLC boosted its position in shares of Mylan by 77.4% during the first quarter. Signaturefd LLC now owns 3,045 shares of the company’s stock valued at $45,000 after buying an additional 1,329 shares during the period. Institutional investors own 85.58% of the company’s stock.

Shares of NASDAQ:MYL traded down $0.23 during trading hours on Thursday, hitting $16.28. The company’s stock had a trading volume of 163,816 shares, compared to its average volume of 4,505,597. Mylan NV has a 52 week low of $12.75 and a 52 week high of $23.11. The company has a debt-to-equity ratio of 0.84, a current ratio of 0.93 and a quick ratio of 0.53. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of 30.57, a P/E/G ratio of 2.18 and a beta of 1.53. The firm’s fifty day moving average price is $16.30 and its 200 day moving average price is $16.86.

Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.16. Mylan had a net margin of 2.35% and a return on equity of 20.43%. The company had revenue of $2.73 billion for the quarter, compared to analyst estimates of $2.74 billion. During the same period last year, the company posted $1.03 earnings per share. Mylan’s revenue was down 4.2% compared to the same quarter last year. On average, equities research analysts predict that Mylan NV will post 4.41 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on MYL shares. Royal Bank of Canada reissued a “buy” rating and set a $26.00 price target on shares of Mylan in a research note on Tuesday, May 12th. UBS Group lifted their target price on Mylan from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. TheStreet upgraded shares of Mylan from a “d+” rating to a “c” rating in a report on Thursday, August 6th. BidaskClub lowered shares of Mylan from a “hold” rating to a “sell” rating in a report on Thursday, July 23rd. Finally, Wells Fargo & Co lowered their price objective on shares of Mylan from $23.00 to $18.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $20.67.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Want to see what other hedge funds are holding MYL? Visit to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with's FREE daily email newsletter.

Leave a Reply